MRD in AML: who, what, when, where, and how?

Kieran D. Sahasrabudhe,Alice S. Mims

DOI: https://doi.org/10.1182/blood.2023022226

IF: 20.3

2024-01-27

Blood

Abstract:In this issue of Blood , Othman et al use retrospective data to show the utility of measurable residual disease (MRD) monitoring of patients with NPM1 acute myeloid leukemia (AML) in de novo treatment using venetoclax-based regimens. 1

hematology

What problem does this paper attempt to address?

Measurable Residual Disease in High-Risk Acute Myeloid Leukemia

Thomas Cluzeau,Roberto M. Lemoli,James McCloskey,Todd Cooper

DOI: https://doi.org/10.3390/cancers14051278

2022-03-01

Cancers

Abstract:Mounting evidence suggests measurable residual disease (MRD) assessments are prognostic in acute myeloid leukemia (AML). High-risk AML encompasses a subset of AML with poor response to therapy and prognosis, with features such as therapy-related AML, an antecedent hematologic disorder, extramedullary disease (in adults), and selected mutations and cytogenetic abnormalities. Historically, few patients with high-risk AML achieved deep and durable remission with conventional chemotherapy; however, newer agents might be more effective in achieving MRD-negative remission. CPX-351 (dual-drug liposomal encapsulation of daunorubicin/cytarabine at a synergistic ratio) demonstrated MRD-negativity rates of 36–64% across retrospective studies in adults with newly diagnosed high-risk AML and 84% in pediatric patients with first-relapse AML. Venetoclax (BCL2 inhibitor) demonstrated MRD-negativity rates of 33–53% in combination with hypomethylating agents for high-risk subgroups in studies of older adults with newly diagnosed AML who were ineligible for intensive therapy and 65% in combination with chemotherapy in pediatric patients with relapsed/refractory AML. However, there is no consensus on optimal MRD methodology in AML, and the use of different techniques, sample sources, sensitivity thresholds, and the timing of assessments limit comparisons across studies. Robust MRD analyses are needed in future clinical studies, and MRD monitoring should become a routine aspect of AML management.

oncology
Measurable residual disease monitoring in AML: Prospects for therapeutic decision‐making and new drug development

Nicholas J. Short,Richard Dillon

DOI: https://doi.org/10.1002/ajh.27482

IF: 13.265

2024-09-27

American Journal of Hematology

Abstract:Measurable residual disease (MRD) is strongly associated with risk of relapse and long‐term survival outcomes in patients with acute myeloid leukemia (AML). Apart from its clear prognostic impact, MRD information is also increasingly used to guide therapeutic decision‐making, including selection of appropriate patients for stem cell transplant, use of post‐transplant maintenance, and candidacy for non‐transplant maintenance therapies or MRD‐directed clinical trials. While much progress has been made in accurately assessing MRD and understanding its clinical importance, many questions remain about how to optimize MRD testing and guide treatment decisions for individual patients. In this review, we discuss the common methods to assess MRD in AML and the prognostic impact of MRD across common clinical scenarios. We also review emerging and investigational strategies to target MRD and discuss some of the important unanswered questions and challenges in the field.

hematology
Molecular MRD Assessment in Acute Myeloid Leukemias

Patkar,Nikhil

DOI: https://doi.org/10.1055/s-0043-1762921

2023-04-18

Indian Journal of Medical and Paediatric Oncology

Abstract:Detection of measurable residual disease (MRD) is of significant value in the management of acute myeloid leukemia (AML) patients. Along with multicolor flowcytometry (MFC), molecular techniques form an integral tool in AML MRD detection. Multiple studies have reiterated the role of molecular MRD evaluation in AML at defined timepoints during the course of therapy, helping in risk stratification, prediction of relapse, and as guide for pre-emptive therapy. The latest World Health Organization (WHO) classification (WHO-HEME5) has refined the classification of AML bringing forth newer entities defined by molecular abnormalities, especially fusions. AML is a clonally heterogeneous disease characterized by a spectrum of multiple molecular abnormalities including gene mutations and fusions. Accordingly, the molecular methods employed are also diverse and need robust technical standardization in clinical laboratories. Real-time quantitative polymerase chain reaction (PCR), digital PCR, and next-generation sequencing (NGS) are the major molecular platforms for AML MRD. The European LeukemiaNet (ELN) MRD Working Party consensus document recently updated in 2021 for the first time has reflected on the technical recommendations for NGS MRD in AML and stressed the value of an integrated approach. It is, therefore, desirable for physicians, scientists, and pathologists alike to thoroughly understand these molecular methods for appropriate utilization and interpretation. In this article, we discuss the various facets of molecular methods for MRD detection in AML including technical requirements, advantages, drawbacks, and applications.

English Else
MRD in Acute Leukemias: Lessons Learned from Acute Promyelocytic Leukemia

David Kegyes,Praveena S. Thiagarajan,Gabriel Ghiaur

DOI: https://doi.org/10.3390/cancers16183208

2024-09-21

Cancers

Abstract:Introduction: Advances in molecular biology, polymerase chain reaction (PCR), and next-generation sequencing (NGS) have transformed the concept of minimal residual disease (MRD) from a philosophical idea into a measurable reality. Current Treatment Paradigms and Lessons Learned from APL: Acute promyelocytic leukemia (APL) leads the way in this transformation, initially using PCR to detect MRD in patients in remission, and more recently, aiming to eliminate it entirely with modern treatment strategies. Along the way, we have gained valuable insights that, when applied to other forms of acute leukemia, hold the potential to significantly improve the outcomes of these challenging diseases. Does the BM Microenvironment Play a Role in MRD?: In this review, we explore the current use of MRD in the management of acute leukemia and delve into the biological processes that contribute to MRD persistence, including its overlap with leukemia stem cells and the role of the bone marrow microenvironment.

oncology
Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?

Firas El Chaer,Anthony J. Perissinotti,Sanam Loghavi,Amer M. Zeidan

DOI: https://doi.org/10.1038/s41375-024-02458-6

2024-11-05

Leukemia

Abstract:The use of measurable residual disease (MRD) as a biomarker for prognostication, risk stratification, and therapeutic decision-making in acute myeloid leukemia (AML) is gaining prominence. MRD monitoring for NPM1 -mutated and core-binding factor AML using PCR techniques is well-established for assessing disease after intensive chemotherapy. AML with persistent FLT3 -ITD MRD post-intensive chemotherapy and pre-allogeneic hematopoietic cell transplantation (pre-allo-HCT) is associated with an increased risk of relapse and lower survival. Pre-allo-HCT MRD is an independent risk factor for post-allo-HCT outcomes, including relapse and death. Therefore, preemptive interventions on the natural history of MRD positivity are an active area of research beyond its initial prognostic function. Targeting MRD in AML with innovative treatment strategies can improve patient outcomes.

oncology,hematology
MRD in Philadelphia Chromosome-Positive ALL: Methodologies and Clinical Implications

Valerie Tran,Kiarash Salafian,Kenan Michaels,Caroline Jones,Daniel Reed,Michael Keng,Firas El Chaer

DOI: https://doi.org/10.1007/s11899-024-00736-9

2024-06-19

Current Hematologic Malignancy Reports

Abstract:Measurable residual disease (MRD) is integral in the management of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). This review discusses the current methods used to evaluate MRD as well as the interpretation, significance, and incorporation of MRD in current practice.

oncology,hematology
Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine

Shin Yeu Ong,Melinda Tan Si Yun,Nurul Aidah Abdul Halim,Dheepa Christopher,Wei Ying Jen,Christian Gallardo,Angeline Tan Hwee Yim,Yeow Kheong Woon,Heng Joo Ng,Melissa Ooi,Gee Chuan Wong

DOI: https://doi.org/10.3390/cancers14153576

2022-07-23

Cancers

Abstract:The prognostic value of measurable residual disease (MRD) by flow cytometry in acute myeloid leukemia (AML) patients treated with non-intensive therapy is relatively unexplored. The clinical value of MRD threshold below 0.1% is also unknown after non-intensive therapy. In this study, MRD to a sensitivity of 0.01% was analyzed in sixty-three patients in remission after azacitidine/venetoclax treatment. Multivariable cox regression analysis identified prognostic factors associated with cumulative incidence of relapse (CIR), progression-free survival (PFS) and overall survival (OS). Patients who achieved MRD < 0.1% had a lower relapse rate than those who were MRD ≥ 0.1% at 18 months (13% versus 57%, p = 0.006). Patients who achieved an MRD-negative CR had longer median PFS and OS (not reached and 26.5 months) than those who were MRD-positive (12.6 and 10.3 months, respectively). MRD < 0.1% was an independent predictor for CIR, PFS, and OS, after adjusting for European Leukemia Net (ELN) risk, complex karyotype, and transplant (HR 5.92, 95% CI 1.34-26.09, p = 0.019 for PFS; HR 2.60, 95% CI 1.02-6.63, p = 0.046 for OS). Only an MRD threshold of 0.1%, and not 0.01%, was predictive for OS. Our results validate the recommended ELN MRD cut-off of 0.1% to discriminate between patients with improved CIR, PFS, and OS after azacitidine/venetoclax therapy.

oncology
Detection methods and prognosis implications of measurable residual disease in acute myeloid leukemia

Lan, Jianping

DOI: https://doi.org/10.1007/s00277-024-06008-z

2024-09-17

Annals of Hematology

Abstract:Measurable residual disease (MRD) in acute myeloid leukemia (AML) refers to the quantity of residual leukemic cells in a patient after treatment.According to the latest agreements, MRD in AML offering essential prognostic insights. However, there is ongoing debate regarding MRD-based monitoring and treatment strategies. There are multiple platforms for detecting MRD, each varying in sensitivity and suitability for different patients. MRD not only predicts treatment outcomes but also serves as an indicator of treatment effectiveness and a prognostic biomarker. In AML, most retrospective studies indicate that patients who are MRD-positive or show increasing MRD levels at specific time points during remission have significantly higher risks of relapse and mortality compared to MRD-negative patients. Although achieving MRD-negative status can improve patient prognosis, the possibility of relapse remains. Despite the correlation between MRD and clinical outcomes, MRD assessment methods are not yet standardized, leading to discrepancies in results across different techniques. To provide reliable MRD results, it is essential to optimize and standardize MRD detection methods. Methods for assessing MRD include multiparameter flow cytometry (MFC) and molecular assays, chosen based on disease characteristics. This review focuses on currently available MRD detection methods and discusses how the prognostic value of MRD test results informs personalized treatment strategies for AML patients.

hematology
Achieving MRD negativity in AML: how important is this and how do we get there?

Christopher S. Hourigan

DOI: https://doi.org/10.1182/hematology.2022000323

2022-12-10

Hematology, the ASH Education Program

Abstract:Multiple studies have demonstrated that patients with acute myeloid leukemia (AML) who have measurable residual disease (MRD) detected during or after treatment have higher relapse rates and worse survival than similar patients testing negative. Updated response criteria for AML reflect the understanding that achievement of complete remission (CR) with no detectable MRD using high-sensitivity tests represents a superior response over conventional cytomorphological CR alone. Potential use cases for AML MRD testing are diverse and include patient selection for clinical trials and therapeutic assignment, early relapse detection and intervention during sequential monitoring, and drug development, including deep quantification for antileukemia efficacy and as a surrogate endpoint for overall survival in regulatory approvals. Testing for AML MRD has not, however, been harmonized, and many technical and clinical questions remain. The implications of MRD test results for specific therapeutic combinations, molecular subsets, test types, treatment time points, sample types, and patient characteristics remain incompletely defined. No perfect AML MRD test or testing strategy currently exists, and the evidence basis for clinical recommendations in this rare disease is sparse but growing. It is unproven whether conversion of an MRD test result from positive to negative by additional therapeutic intervention improves relapse risk and survival. Several national- and international-level consortia have recently been initiated to advance the generation and collection of evidence to support the use of AML MRD testing in clinical practice, drug development, and regulatory approvals.
Old and New Concepts

Chea,Rigolot,Canali,Vergez

DOI: https://doi.org/10.3390/ijms25042150

IF: 5.6

2024-02-11

International Journal of Molecular Sciences

Abstract:Minimal residual disease (MRD) is of major importance in onco-hematology, particularly in acute myeloid leukemia (AML). MRD measures the amount of leukemia cells remaining in a patient after treatment, and is an essential tool for disease monitoring, relapse prognosis, and guiding treatment decisions. Patients with a negative MRD tend to have superior disease-free and overall survival rates. Considerable effort has been made to standardize MRD practices. A variety of techniques, including flow cytometry and molecular methods, are used to assess MRD, each with distinct strengths and weaknesses. MRD is recognized not only as a predictive biomarker, but also as a prognostic tool and marker of treatment efficacy. Expected advances in MRD assessment encompass molecular techniques such as NGS and digital PCR, as well as optimization strategies such as unsupervised flow cytometry analysis and leukemic stem cell monitoring. At present, there is no perfect method for measuring MRD, and significant advances are expected in the future to fully integrate MRD assessment into the management of AML patients.

biochemistry & molecular biology,chemistry, multidisciplinary
Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practice

Brian C. Shaffer,Partow Kebriaei,Marcos de Lima,Antonio M. Jimenez Jimenez

DOI: https://doi.org/10.1038/s41409-024-02481-2

2024-11-25

Bone Marrow Transplantation

Abstract:Measurable residual disease (MRD) testing in patients with acute myelogenous leukemia (AML) represents a heterogenous assessment process designed to quantify leukemia-specific biomarkers that are not ascertainable by routine pathologic evaluation. The most common tools used to assess MRD are multiparameter flow cytometry (MPFC), and polymerase chain reaction (PCR) based tools, including quantitative or digital droplet PCR (qPCR, ddPCR), or next-generation sequencing (NGS) technologies. Collectively, MRD assessments have become an important clinical tool in the management of patients with AML. Despite progress, significant questions remain with respect to the appropriate timing, frequency, and methodology of MRD assessment, and whether or how to adapt therapy based on MRD results. Recent data from the Pre-MEASURE study, a retrospective cohort analysis of error corrected NGS based MRD assessment prior to allogeneic hematopoietic cell transplantation (alloHCT) in patients with AML, provides additional key information with respect to the emerging role of NGS-based technology in MRD assessment. In the context of this review, we evaluate the Pre-MEASURE study as well as other recent, high-quality assessments of MRD in AML. Our focus is to provide a practical assessment of the use of emerging MRD technologies in patients with AML with an emphasis on the role of peri-transplant MRD for the practicing clinician.

oncology,immunology,hematology,transplantation
Abstract 2793: Minimal residual disease (MRD) as a predictive biomarker/endpoint for novel drug development

Nicholas Jones,Brian Ngo,Floyd Davis,Benjamin Fancke

DOI: https://doi.org/10.1158/1538-7445.am2022-2793

IF: 11.2

2022-06-17

Cancer Research

Abstract:MRD is defined as the continual presence of cancer cells in patients post therapy that is below the threshold of detection by conventional morphologic or radiologic assessments. Monitoring patient status clinically as MRD negative or MRD positive has become the basis for predicting outcomes, remission or reoccurrence, as well as determining therapeutic options. The three primary methods to assess MRD status in patients include Flow Cytometry (FC), Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS). All three are highly quantitative measurements with a high degree of sensitivity to detect "new" circulating tumor cells or ctDNA that can potentially indicate disease recurrence before it happens. The choice of MRD methodology usually depends on the tumor type, liquid or solid. Flow Cytometry has been widely used to monitor MRD status in patients with hematologic malignancies. Specifically designed MRD panels have been used clinically in CLL, MM, CML and AML patients. In addition to its prognostic/diagnostic relevance, recent guidance by the FDA is now driving the use of MRD testing as a predictive biomarker/endpoint for novel cancer drug development. NeoGenomics Pharma Services has provided flow cytometry MRD expertise to multiple sponsors conducting clinical trials to evaluate the effectiveness of novel cancer therapy. In a CLL study, NeoGenomics employed the ERIC MRD assessment to monitor patient status during therapeutic intervention at various points throughout treatment. Representative patient data show progression from full, active disease prior to therapy to non-detectable disease levels below 0.01%MRD. These examples show patient progression through multiple cycles of treatment to full remission. Clearly, this is an example of how MRD can serve as the primary "biomarker" to evaluate a patient's response to novel drug therapy in clinical trials. This presentation will further discuss the data and the relevance of MRD testing to support new drug development. Citation Format: Nicholas Jones, Brian Ngo, Floyd Davis, Benjamin Fancke. Minimal residual disease (MRD) as a predictive biomarker/endpoint for novel drug development [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 2793.

oncology
Monitoring Minimal Residual Disease in ALL and AML

Peter Bader,Hermann Kreyenberg,Gert Ossenkoppele

DOI: https://doi.org/10.1007/978-3-030-02278-5_57

2018-12-13

Abstract:In ALL evaluation of molecular treatment response, assessment of minimal residual disease (MRD) is a substantial independent predictor of outcome, as proven by randomized studies (Conter et al. 2010; Gökbuget et al.
Measurable residual disease in hematopoietic stem cell transplantation-eligible patients with acute myeloid leukemia: clinical significance and promising therapeutic strategies

Daria Gaut,Monica Mead

DOI: https://doi.org/10.1080/10428194.2020.1827251

2020-11-02

Abstract:<span>Allogeneic hematopoietic stem cell transplantation (alloHCT) results in improved outcomes for acute myeloid leukemia (AML) patients compared to consolidation chemotherapy in transplant-eligible patients with adverse-risk disease. Despite achieving a complete remission (CR) to initial therapy, defined as <5% bone marrow blasts with recovery of peripheral blood elements, a large number of patients suffer disease relapse following alloHCT. There is a growing focus on minimal or measurable residual disease (MRD) in patients with AML, variably defined using multiparametric flow cytometry and nucleic acid sequencing techniques, to detect levels of disease not included in current CR terminology. MRD has emerged as an important prognostic tool in AML and may improve risk stratification, further refine selection of post-remission treatment, and provide an opportunity for therapeutic intervention. Herein, we review MRD detection methods, timing of measurement, prognostic implications, and MRD-directed therapy in AML patients undergoing alloHCT.</span>

oncology,hematology
Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)

Enrico Maffini,Myriam Labopin,Dietrich Wilhelm Beelen,Nicolaus Kroeger,Mutlu Arat,Keith M. O. Wilson,Jacques-Olivier Bay,Arnold Ganser,Hans Martin,Jakob Passweg,Panagiotis D. Kottaridis,Ibrahim Yakoub-Agha,Rocio Parody Porras,Eva Maria Wagner,Jordi Esteve,Francesco Lanza,Arnon Nagler,Mohamad Mohty

DOI: https://doi.org/10.1038/s41409-022-01748-w

2022-07-15

Bone Marrow Transplantation

Abstract:Measurable residual disease (MRD) assessment before allogeneic hematopoietic cell transplantation (HCT) may help physicians to identify a subgroup of patients at high risk of relapse for de novo acute myeloid leukemia (AML) but its relevance among patients affected by secondary AML (sAML) is still unknown. We assessed the impact of MRD among 318 adult patients with sAML who received an allogeneic HCT in first complete remission. At the time of HCT, a total of 208 (65%) patients achieved MRD negativity, while 110 (35%) had positive MRD. 2-year overall survival (OS) was 58.8 % (95% CI 52.2–64.9) with leukemia-free survival (LFS) of 50.0 % (95% CI 43.7–56.1), relapse incidence of 34.2% (95% CI 28.4–40.1) and non-relapse mortality (NRM) of 23.3 % (95% CI 19–27.7) for the entire cohort. In multivariate analysis, HCT recipients with KPS ≥ 90 experienced less disease recurrence (HR 0.61, 95% CI 0.4–0.94) with better LFS (HR 0.63, 95% CI 0.44–0.89) and OS (HR 0.58, 95% CI 0.39–0.86). There were no differences in major clinical endpoints between patients with MRD-positive and MRD-negative status at the time of HCT. Pre-transplantation assessment of MRD was not informative on post-HCT outcomes in this retrospective registry-based analysis among patients affected by sAML.

oncology,immunology,hematology,transplantation
Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)

Eduardo Rodríguez-Arbolí,Megan Othus,Sylvie D. Freeman,Francesco Buccisano,Lok Lam Ngai,Ian Thomas,Raffaele Palmieri,Jacqueline Cloos,Sean Johnson,Elisa Meddi,Nigel H. Russell,Adriano Venditti,Patrycja Gradowska,Gert J. Ossenkoppele,Bob Löwenberg,Roland B. Walter

DOI: https://doi.org/10.1038/s41375-024-02378-5

2024-08-23

Leukemia

Abstract:Multiparameter flow cytometry (MFC)-based MRD testing is increasingly utilized in AML, but methodologies and assay characteristics vary substantially [1,2,3]. Nonetheless, following regulatory authorities' guidance MRD assays be validated 1-log below the chosen threshold for clinical decision-making, the European LeukemiaNet (ELN) MRD Working Party presently defines MRD positivity uniformly at 0.1% [2]. Yet, agnostic to assay specifications, risk stratification may be suboptimal. We examined this possibility using 4 well-annotated cohorts of AML patients in morphologic remission in which MRD results did not guide treatment decisions. Our dataset included patients from GIMEMA ( n = 182, from EORTC/GIMEMA AML-10 and AML-12), HOVON/SAKK ( n = 171, from HOVON/SAKK 42A), MRC/NCRI ( n = 846, from AML17), and Seattle ( n = 861; adults allografted in first morphologic remission). All patients were treated on IRB-approved research protocols or standard treatment protocols and gave consent in accordance with the Declaration of Helsinki; for details, see online supplement. For GIMEMA, cases expressing a leukemia-associated immunophenotype (LAIP) were re-analyzed with a combination of 6–8 markers to define a LAIP fingerprint for MRD tracking [4,5,6,7]. For HOVON/SAKK, a suitable LAIP comprising ≥10% of the CD45 dim blasts was identified at diagnosis using a 4-color assay and monitored during follow-up. For MRC/NCRI, MFC-MRD testing was centrally performed with a standardized 7/8-color assay that screened for "different-from-normal" LAIPs pretreatment and tracked these ( ∼ 0.02–0.05% sensitivity) but also applied the different-from-normal approach in follow-up samples to detect LAIP changes ( ∼ 0.05–0.1% sensitivity). Only samples with pretreatment LAIPs could be reported as MRD neg . For Seattle, pre-transplant bone marrows were subjected to 10-color MFC-MRD testing with a panel of 3 antibody combinations, collecting up to 1 million events/tube [8, 9]. MRD was identified using a "different-from-normal" approach, with detection sensitivity to a level of 0.1% in most cases and at lower levels in progressively smaller patients subsets [8, 9]. For all cohorts, only samples of sufficient quality for MRD testing were included in our analyses, which were conducted under a research protocol approved by the Fred Hutchinson Cancer Center's Institutional Review Board.

oncology,hematology
Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions

Jennifer Moritz,Antonia Schwab,Andreas Reinisch,Armin Zebisch,Heinz Sill,Albert Wölfler

DOI: https://doi.org/10.3390/biomedicines12030599

IF: 4.757

2024-03-08

Biomedicines

Abstract:Acute myeloid leukemia (AML) is an aggressive malignant disease with a high relapse rate due to the persistence of chemoresistant cells. To some extent, these residual cells can be traced by sensitive flow cytometry and molecular methods resulting in the establishment of measurable residual disease (MRD). The detection of MRD after therapy represents a significant prognostic factor for predicting patients' individual risk of relapse. However, due to the heterogeneity of the disease, a single sensitive method for MRD detection applicable to all AML patients is lacking. This review will highlight the advantages and limitations of the currently available detection methods—PCR, multiparameter flow cytometry, and next generation sequencing—and will discuss emerging clinical implications of MRD test results in tailoring treatment of AML patients.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma

Joaquin Martinez-Lopez,Sandy W. Wong,Nina Shah,Natasha Bahri,Kaili Zhou,Ying Sheng,Chiung-Yu Huang,Thomas Martin,Jeffrey Wolf

DOI: https://doi.org/10.1182/bloodadvances.2020002037

IF: 7.642

2020-07-24

Blood Advances

Abstract:Abstract Few clinical studies have reported results of measurable residual disease (MRD) assessments performed as part of routine practice. Herein we present our single-institution experience assessing MRD in 234 multiple myeloma (MM) patients (newly diagnosed [NDMM = 159] and relapsed [RRMM = 75]). We describe the impact of depth, duration, and direction of response on prognosis. MRD assessments were performed by next-generation sequencing of immunoglobulin genes with a sensitivity of 10−6. Those achieving MRD negativity at 10−6, as well as 10−5, had superior median progression-free survival (PFS). In the NDMM cohort, 40% of the patients achieved MRD negativity at 10−6 and 59% at 10−5. Median PFS in the NDMM cohort was superior in those achieving MRD at 10−5 vs <10−5 (PFS: 87 months vs 32 months; P < .001). In the RRMM cohort, 36% achieved MRD negativity at 10−6 and 47% at 10−5. Median PFS was superior for the RRMM achieving MRD at 10−5 vs <10−5 (PFS: 42 months vs 17 months; P < .01). Serial MRD monitoring identified 3 categories of NDMM patients: (A) patients with ≥3 MRD 10−6 negative samples, (B) patients with detectable but continuously declining clonal numbers, and (C) patients with stable or increasing clonal number (≥1 log). PFS was superior in groups A and B vs C (median PFS not reached [NR], NR, 55 respectively; P < .001). This retrospective evaluation of MRD used as part of clinical care validates MRD as an important prognostic marker in NDMM and RRMM and supports its use as an endpoint in future clinical trials as well as for clinical decision making.

hematology
Minimal Residual Disease Status in Acute Myeloid Leukemia Patients Undergoing T-Cell Replete Haploidentical Transplantation. an Analysis From the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (Ebmt)

Jonathan Canaani,Myriam Labopin,Xiao-Jun Huang,Fabio Ciceri,Maria Teresa Van Lint,Benedetto Bruno,Stella Santarone,Jose L. Diez-Martin,Didier Blaise,Simona Sica,Depei Wu,Mohamad Mohty,Arnon Nagler

DOI: https://doi.org/10.1016/j.bbmt.2017.12.684

2018-01-01

Biology of Blood and Marrow Transplantation

Abstract:Background: Assessment of minimal residual disease (MRD) is actively transitioning into the mainstream routine evaluation of response to therapy and prognostication schemes in patients (pts) with acute myeloid leukemia (AML). While it is well established that pre-transplant positive MRD studies predict for relapse and transplantation outcome in pts transplanted either from matched sibling donors or matched unrelated donors, it is currently unknown whether MRD has comparable prognostic value for pts undergoing haploidentical stem cell transplantation (haplo-SCT). Methods: To analyze the prognostic impact of MRD in haplo-SCT, we performed a retrospective analysis using the ALWP multicenter registry. All adult AML pts with known MRD status at transplant who underwent a first T-cell replete related haplo-HCT in first or second complete remission from 2006 to 2016 were included. Results: Three hundred ninety-three pts of whom 265 were MRD negative and 128 were MRD positive prior to transplant met the study inclusion criteria. Median follow-up period was 26 and 15 months for MRD negative and positive pts, respectively. Compared to MRD positive pts, MRD negative pts were more likely to be NPM1wt (65% vs. 46%; P = .01) as well as harbor poor risk cytogenetics (15% vs. 7%; P < .001). Both groups of pts did not differ to a significant degree in terms of patient age, performance status, FLT3-ITDstatus, conditioning intensity, and post-transplant immunomodulation strategy (namely, use of post-transplant cyclophosphamide or anti-thymocyte globulin). In multivariate analysis, MRD negative patients experienced lower relapse incidence [Hazard ratio (HR) = .31, confidence interval (CI) 95%, .18-0.56; P < .0001] and better leukemia-free survival (LFS) (HR = .62, CI 95%, .41-0.93; P = .023) compared to MRD positive pts. Non-relapse mortality (HR = 1.34, CI 95%, .68-2.62; P = .39) and acute graft versus host disease (HR = 1.09, CI 95%, .64-1.84; P = .78) were not significantly different between both groups. Similarly, overall survival (OS) (HR = .7, CI 95%, .44-1.12; P = .14) as well as graft versus host disease-free/relapse-free survival (HR = .71, CI 95%, .48-1.04; P = .078) were not significantly impacted by MRD status. Subset analysis for MRD positive pts revealed that pts with CMV+ donors experienced decreased relapse rates (HR = .32, CI 95%, .15-0.65; P = .001) as well as increased survival (HR = .37, CI 95%, .17-0.8; P = .012). No significant predictive factors for clinical outcome were identified in the MRD negative patient subset. A landmark analysis at 6 months (figure) suggests that the clinical benefit of pre-transplant MRD negativity in terms of relapse, OS, LFS, and GRFS is realized at this time point. Conclusion: MRD negativity at transplant is associated with a reduced relapse rate and improved LFS in AML patients undergoing T-cell replete haplo-SCT.
Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC‐MRD and treatment guidance for elderly patients

Yue Sun,Gelan Zhu,Hua Zhong

DOI: https://doi.org/10.1111/ejh.14187

2024-02-13

European Journal Of Haematology

Abstract:Acute myeloid leukemia (AML) is distinguished by clonal growth of myeloid precursor cells, which impairs normal hematopoiesis. Minimal residual disease (MRD) refers to the residual leukemia cells that persist after chemotherapy. Patients who test positive for MRD have a higher likelihood of experiencing a recurrence, regardless of the specific chemotherapy approach used. Multi‐parameter flow cytometry (MFC), polymerase chain reaction (PCR), and next‐generation sequencing (NGS) are commonly employed techniques for identifying MRD. In the context of AML, patients are frequently monitored for measurable residual disease via multi‐parameter flow cytometry (MFC‐MRD). In order to explore recent advancements in AML and MRD diagnosis, an extensive search of the PubMed database was conducted, focusing on relevant research in the past 20 years. This review aims to examine various MRD monitoring methods, the optimal time points for assessment, as well as different specimen types used. Additionally, it underscores the significance of MFC‐MRD assessment in guiding the treatment of elderly AML.

hematology

MRD in AML: who, what, when, where, and how?

Measurable Residual Disease in High-Risk Acute Myeloid Leukemia

Measurable residual disease monitoring in AML: Prospects for therapeutic decision‐making and new drug development

Molecular MRD Assessment in Acute Myeloid Leukemias

MRD in Acute Leukemias: Lessons Learned from Acute Promyelocytic Leukemia

Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?

MRD in Philadelphia Chromosome-Positive ALL: Methodologies and Clinical Implications

Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine

Detection methods and prognosis implications of measurable residual disease in acute myeloid leukemia

Achieving MRD negativity in AML: how important is this and how do we get there?

Old and New Concepts

Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practice

Abstract 2793: Minimal residual disease (MRD) as a predictive biomarker/endpoint for novel drug development

Monitoring Minimal Residual Disease in ALL and AML

Measurable residual disease in hematopoietic stem cell transplantation-eligible patients with acute myeloid leukemia: clinical significance and promising therapeutic strategies

Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)

Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)

Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions

Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma

Minimal Residual Disease Status in Acute Myeloid Leukemia Patients Undergoing T-Cell Replete Haploidentical Transplantation. an Analysis From the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (Ebmt)

Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC‐MRD and treatment guidance for elderly patients